20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vaxcyte Inc (PCVX) operates in the BIOTECHNOLOGY industry and is headquartered in San Carlos, United States with about 507 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, PCVX reported $0M in revenue and ($767M) in net income.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | — | ($16M) | ($75M) | ($9M) | ($2M) | ($1M) | ($1M) | ($1M) | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($1.2B) | ($924M) | ($570M) | ($468M) | ($232M) | ($104M) | ($90M) | ($54M) | ($36M) | ($18M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($1.1B) | ($767M) | ($464M) | ($402M) | ($223M) | ($100M) | ($89M) | ($50M) | ($29M) | ($17M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($1.1B) | ($742M) | ($448M) | ($392M) | ($214M) | ($97M) | ($88M) | ($49M) | ($28M) | ($17M) |
| Earnings Per Share (EPS) | $-7.64 | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 | $-1.03 | $-1.15 | $-4.83 |
| Shares Outstanding (M) | 144M | 136M | 122M | 97M | 65M | 52M | 30M | 49M | — | 4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($6M) | $5M | — | ($5M) | — | — | ($5M) |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($303M) | ($346M) | ($274M) | ($242M) | ($226M) | ($181M) | ($162M) | ($140M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($284M) | ($321M) | ($247M) | ($213M) | ($167M) | ($141M) | ($137M) | ($103M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($292M) | ($315M) | ($235M) | ($210M) | ($162M) | ($136M) | ($53M) | ($135M) |
| Earnings Per Share (EPS) | $-1.97 | $-2.30 | $-1.81 | $-1.56 | $-1.22 | $-1.04 | $-1.12 | $-0.83 |
| Shares Outstanding (M) | 144M | 140M | 136M | 136M | 136M | 136M | 123M | 124M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($1.2B) | ($656M) | ($453M) | ($297M) | ($171M) | ($121M) | ($47M) | ($47M) | ($30M) | $0M |
| Capital Expenditures (CapEx) | $52M | $14M | $22M | $68M | $6M | $7M | $1M | $1M | $2M | $0M |
| Free Cash Flow (FCF) | ($1.2B) | ($669M) | ($475M) | ($365M) | ($176M) | ($128M) | ($48M) | ($48M) | ($32M) | $0M |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | $0M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($232M) | ($281M) | ($225M) | ($143M) | ($121M) | ($166M) | ($111M) | ($61M) |
| Capital Expenditures (CapEx) | $4M | $15M | $6M | $12M | $20M | $27M | $30M | $38M |
| Free Cash Flow (FCF) | ($237M) | ($295M) | ($230M) | ($155M) | ($141M) | ($193M) | ($141M) | ($99M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.1B | $3.0B | $3.5B | $1.4B | $1.0B | $324M | $393M | $66M | $71M | $40M |
| Cash & Cash Equivalents | $183M | $174M | $388M | $397M | $835M | $69M | $386M | $59M | $66M | $36M |
| Total Liabilities | $380M | $360M | $205M | $167M | $53M | $40M | $47M | $172M | $129M | $9M |
| Total Debt (Short + Long-Term) | $7M | $6M | $6M | $7M | $6M | $5M | $0M | $1M | $4M | $4M |
| Total Shareholders' Equity | $2.8B | $2.7B | $3.3B | $1.2B | $954M | $284M | $346M | ($106M) | ($58M) | $31M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PCVX viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms